Ubs Asset Management Americas Inc Bristol Myers Squibb CO Transaction History

Ubs Asset Management Americas Inc

$345 Billion
Q2 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 16,072,405 shares of BMY stock, worth $818 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares

16,072,405

Previous 12,195,082 31.79%

Holding current value

$818 Million

Previous $661 Million 0.93%

% of portfolio

0.19%

Previous 0.24%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$40.25 - $52.99 $156 Million - $205 Million	3,877,323 Added 31.79%	16,072,405 $667 Million
Q1 2024 May 15, 2024	BUY	$47.98 - $54.4 $33.4 Million - $37.9 Million	696,680 Added 6.06%	12,195,082 $661 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $20.2 Million - $24.1 Million	415,739 Added 3.75%	11,498,402 $590 Million
Q3 2023 Nov 13, 2023	SELL	$57.89 - $64.73 $5.06 Million - $5.66 Million	-87,492 Reduced 0.78%	11,082,663 $643 Million
Q1 2023 May 15, 2023	BUY	$65.71 - $74.53 $17.6 Million - $20 Million	267,876 Added 2.46%	11,170,155 $774 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $46.3 Million - $54.8 Million	675,732 Added 6.61%	10,902,279 $784 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $21,997 - $13 Million	169,209 Added 1.68%	10,226,547 $727 Million
Q2 2022 Aug 12, 2022	BUY	$72.62 - $79.98 $33.1 Million - $36.4 Million	455,505 Added 4.74%	10,057,338 $774 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $14.6 Million - $17.5 Million	237,872 Added 2.54%	9,601,833 $701 Million
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $17.9 Million - $20.8 Million	332,905 Added 3.69%	9,363,961 $584 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $7.36 Million - $8.63 Million	-124,452 Reduced 1.36%	9,031,056 $534 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $19.4 Million - $21.2 Million	-314,034 Reduced 3.32%	9,155,508 $612 Million
Q1 2021 May 14, 2021	BUY	$59.34 - $66.74 $236,054 - $265,491	3,978 Added 0.04%	9,469,542 $598 Million
Q4 2020 Mar 01, 2021	BUY	$57.74 - $65.43 $48.4 Million - $54.8 Million	837,646 Added 9.71%	9,465,564 $587 Million
Q3 2020 Nov 13, 2020	BUY	$57.43 - $63.64 $15.4 Million - $17 Million	267,440 Added 3.2%	8,627,918 $520 Million
Q2 2020 Aug 14, 2020	SELL	$54.82 - $64.09 $85 Million - $99.4 Million	-1,550,281 Reduced 15.64%	8,360,478 $492 Million
Q1 2020 May 15, 2020	BUY	$46.4 - $67.43 $22.2 Million - $32.3 Million	478,831 Added 5.08%	9,910,759 $552 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $129 Million - $168 Million	2,624,680 Added 38.56%	9,431,928 $605 Million
Q3 2019 Nov 14, 2019	BUY	$42.77 - $50.71 $15.2 Million - $18 Million	354,581 Added 5.5%	6,807,248 $345 Million
Q2 2019 Aug 15, 2019	BUY	$44.62 - $49.34 $24.2 Million - $26.8 Million	542,204 Added 9.17%	6,452,667 $0
Q1 2019 May 14, 2019	BUY	$45.12 - $53.8 $15.2 Million - $18.2 Million	337,977 Added 6.07%	5,910,463 $0
Q4 2018 Feb 13, 2019	BUY	$48.76 - $63.23 $22.8 Million - $29.6 Million	467,668 Added 9.16%	5,572,486 $290 Million
Q3 2018 Nov 14, 2018	SELL	$55.19 - $62.25 $1.8 Million - $2.03 Million	-32,609 Reduced 0.63%	5,104,818 $0
Q2 2018 Aug 14, 2018	SELL	$50.53 - $62.98 $8.79 Million - $11 Million	-174,046 Reduced 3.28%	5,137,427 $0
Q1 2018 May 14, 2018	BUY	$59.92 - $68.98 $1.83 Million - $2.1 Million	30,470 Added 0.58%	5,311,473 $0
Q4 2017 Feb 09, 2018	BUY	$59.94 - $65.35 $23.2 Million - $25.3 Million	387,094 Added 7.91%	5,281,003 $0
Q3 2017 Nov 13, 2017	BUY	$55.23 - $63.74 $270 Million - $312 Million	4,893,909	4,893,909 $0

Others Institutions Holding BMY

# of Institutions

2,400

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $108B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Bristol Myers Squibb CO Transaction History